Fulgent Genetics Stock News

Shares of Fulgent Genetics (FLGT) are down 12% in after-hours trading despite quarterly results that beat on the top and bottom lines.

Fulgent Genetics (FLGT) announced a strategic investment in Spatial Genomics.FLGT is investing up to $40M to lead Spatial''s series A financing, which totals ~$56M

Fulgent Genetics press release (FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81.Revenue of $251.7M beats by $60.6M.Shares -5%.Outlook Q1 2022:T otal Revenue of approximately…

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Results: Revenue of $251.7 million Billable tests delivered approximately 2.5 million Core Revenue grew 234%

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

Fulgent Genetics (NASDAQ:FLGT) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, after market close.The consensus EPS Estimate is $2.67 (-56.9% Y/Y) and

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

In the latest trading session, Fullgent Genetics (FLGT) closed at $65.84, marking a -0.98% move from the previous day.

In the latest trading session, Fullgent Genetics (FLGT) closed at $65.84, marking a -0.98% move from the previous day.